156 related articles for article (PubMed ID: 35211673)
1. Medicines for millions of patients.
Rees DC
RSC Med Chem; 2022 Jan; 13(1):7-12. PubMed ID: 35211673
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
3. Mutually Rewarding Academia-Industry Collaborations in the Field of Chemical Biology.
Auberson YP; Grether U; Vauzeilles B; Vázquez O
Chembiochem; 2023 Jun; 24(11):e202300121. PubMed ID: 37140146
[TBL] [Abstract][Full Text] [Related]
4. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
5. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.
Germann PG; Schuhmacher A; Harrison J; Law R; Haug K; Wong G
Hum Genomics; 2013 Mar; 7(1):5. PubMed ID: 23496921
[TBL] [Abstract][Full Text] [Related]
6. Challenges facing drug discovery in vascular disease.
Cowley P; Witherington J
Drug News Perspect; 2005 Dec; 18(10):657-62. PubMed ID: 16491168
[TBL] [Abstract][Full Text] [Related]
7. Advancing novel therapies for neurodegeneration through an innovative model for industry-academia collaborations: A decade of the Eisai-UCL experience.
Atkinson PJ; Swami M; Ridgway N; Roberts M; Kinghorn J; Warner TT; Staddon JM; Takle AK
Drug Discov Today; 2023 Oct; 28(10):103732. PubMed ID: 37541423
[TBL] [Abstract][Full Text] [Related]
8. Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial.
Rockers PC; Laing RO; Ashigbie PG; Onyango MA; Mukiira CK; Wirtz VJ
Lancet Glob Health; 2019 Apr; 7(4):e492-e502. PubMed ID: 30799142
[TBL] [Abstract][Full Text] [Related]
9. Ketamine: stimulating antidepressant treatment?
Malhi GS; Byrow Y; Cassidy F; Cipriani A; Demyttenaere K; Frye MA; Gitlin M; Kennedy SH; Ketter TA; Lam RW; McShane R; Mitchell AJ; Ostacher MJ; Rizvi SJ; Thase ME; Tohen M
BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
[TBL] [Abstract][Full Text] [Related]
10. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
[TBL] [Abstract][Full Text] [Related]
11. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
Biskupiak J; Oderda G; Brixner D; Tang D; Zacker C; Dalal AA
J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
[TBL] [Abstract][Full Text] [Related]
12. Knowledge translation in tri-sectoral collaborations: An exploration of perceptions of academia, industry and healthcare collaborations in innovation adoption.
Ii SS; Fitzgerald L; Morys-Carter MM; Davie NL; Barker R
Health Policy; 2018 Feb; 122(2):175-183. PubMed ID: 29191387
[TBL] [Abstract][Full Text] [Related]
13. Traversing industry and academia in biomedicine: the best of both worlds?
Gilliland DG; Regev A; Schadt EE; Tung J
Nat Rev Genet; 2022 Aug; 23(8):461-466. PubMed ID: 35534711
[TBL] [Abstract][Full Text] [Related]
14. Characterising meaningful patient and public involvement in the pharmaceutical industry research setting: a retrospective quality assessment.
Dews SA; Bassi A; Buckland S; Clements L; Daley R; Davies A; Evett S; Howland S; Kinloch E; Phillips B; Powell G; Preston J; Sterniczuk K; Bohm N
BMJ Open; 2023 Aug; 13(8):e071339. PubMed ID: 37612107
[TBL] [Abstract][Full Text] [Related]
15. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research.
Tuntland T; Ethell B; Kosaka T; Blasco F; Zang RX; Jain M; Gould T; Hoffmaster K
Front Pharmacol; 2014; 5():174. PubMed ID: 25120485
[TBL] [Abstract][Full Text] [Related]
16. Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs.
Lessl M; Schoepe S; Sommer A; Schneider M; Asadullah K
Drug Discov Today; 2011 Apr; 16(7-8):288-92. PubMed ID: 21129498
[TBL] [Abstract][Full Text] [Related]
17. Study protocol for a cluster-randomised controlled trial of an NCD access to medicines initiative: evaluation of Novartis Access in Kenya.
Rockers PC; Wirtz VJ; Vian T; Onyango MA; Ashigbie PG; Laing R
BMJ Open; 2016 Nov; 6(11):e013386. PubMed ID: 27888177
[TBL] [Abstract][Full Text] [Related]
18. The role of modern biology and medicine in drug development in academia and industry.
Blake CA; Barker KL; Sobel BE
Exp Biol Med (Maywood); 2006 Dec; 231(11):1680-1. PubMed ID: 17138752
[TBL] [Abstract][Full Text] [Related]
19. Computational chemistry at Janssen.
van Vlijmen H; Desjarlais RL; Mirzadegan T
J Comput Aided Mol Des; 2017 Mar; 31(3):267-273. PubMed ID: 27995515
[TBL] [Abstract][Full Text] [Related]
20. History and Prospects of Drug Discovery and Development Collaboration between Industry and Academia.
Singh SB; Martin GE; McKittrick B; Crowther J; Fraenkel H; Lunn C; Bayne M; Perkins JB; Gullo V
J Nat Prod; 2024 Apr; 87(4):1235-1245. PubMed ID: 38554098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
